Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Ependymoma

ClinicalTrials.gov lists 225 trials for Ependymoma or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 33.

MeSH D004806 Neoplasms Neoplasm C04 Listed by Orphanet as a rare disease
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 86 Phase 1/2 Phase 1/2 16 Phase 2 Phase 2 74 Phase 2/3 Phase 2/3 1 Phase 3 Phase 3 5 Not applicable Not applicable 18 Observational Observational 25 Phase 1 Phase 1 86 Phase 1/2 Phase 1/2 16 Phase 2 Phase 2 74 Phase 2/3 Phase 2/3 1 Phase 3 Phase 3 5 Not applicable Not applicable 18 Observational Observational 25

Trials per phase (log scale)

219 of the 225 trials are tagged with Ependymoma itself; the rest are tagged with a narrower condition beneath it.

Get the Ependymoma report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Ependymoma trials start? (34)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Not applicable
  • Observational

Top of scale: 20

1991: 2 trials (Phase 2 1, Phase 1 1) 1993: 1 trials (Phase 1/2 1) 1994: 3 trials (Phase 2 1, Phase 1 2) 1996: 3 trials (Not applicable 1, Phase 1 2) 1997: 5 trials (Phase 2 3, Phase 1/2 1, Phase 1 1) 1998: 7 trials (Not applicable 1, Phase 2 3, Phase 1 3) 1999: 3 trials (Phase 2 1, Phase 1 2) 2000: 5 trials (Phase 1/2 1, Phase 1 4) 2001: 8 trials (Observational 1, Not applicable 1, Phase 3 1, Phase 2 2, Phase 1/2 1, Phase 1 2) 2002: 5 trials (Phase 3 1, Phase 2 1, Phase 1 3) 2003: 5 trials (Observational 1, Phase 2 3, Phase 1 1) 2004: 3 trials (Observational 2, Phase 1 1) 2005: 5 trials (Observational 1, Phase 2 1, Phase 1 3) 2006: 9 trials (Observational 2, Not applicable 2, Phase 2/3 1, Phase 2 2, Phase 1 2) 2007: 8 trials (Not applicable 1, Phase 3 1, Phase 2 4, Phase 1 2) 2008: 5 trials (Observational 1, Not applicable 1, Phase 3 1, Phase 2 1, Phase 1 1) 2009: 7 trials (Observational 1, Phase 2 4, Phase 1/2 1, Phase 1 1) 2010: 17 trials (Observational 2, Not applicable 1, Phase 3 1, Phase 2 5, Phase 1/2 1, Phase 1 7) 2011: 9 trials (Observational 1, Not applicable 1, Phase 2 5, Phase 1 2) 2012: 5 trials (Phase 1/2 1, Phase 1 4) 2013: 5 trials (Not applicable 2, Phase 2 1, Phase 1 2) 2014: 4 trials (Not applicable 2, Phase 2 2) 2015: 7 trials (Observational 1, Phase 2 2, Phase 1 4) 2016: 6 trials (Phase 2 2, Phase 1 4) 2017: 20 trials (Observational 1, Not applicable 1, Phase 2 11, Phase 1 7) 2018: 9 trials (Observational 1, Not applicable 1, Phase 2 4, Phase 1 3) 2019: 10 trials (Observational 1, Phase 2 1, Phase 1 8) 2020: 6 trials (Phase 2 4, Phase 1/2 1, Phase 1 1) 2021: 6 trials (Phase 2 2, Phase 1/2 1, Phase 1 3) 2022: 6 trials (Not applicable 1, Phase 2 1, Phase 1/2 1, Phase 1 3) 2023: 6 trials (Observational 4, Not applicable 1, Phase 1 1) 2024: 6 trials (Observational 1, Phase 1/2 3, Phase 1 2) 2025: 5 trials (Observational 2, Phase 2 1, Phase 1/2 1, Phase 1 1)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 12
2025 5
2024 6
2023 6
2022 6
2021 6
2020 6
2019 10
2018 9
2017 20

Showing 10 of 34 earlier years.

Start your 14-day trial Email me all 34 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 14 trials starting in 2026 and about 9 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 18 trials still running at the 2026-10-09 snapshot; registered median of 52 months across 156 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Ependymoma trials in? (7)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 86
Phase 1/2 16
Phase 2 74
Phase 2/3 1
Phase 3 5
Not applicable 18
Observational 25

How many Ependymoma trials are recruiting? (8)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 10
Recruiting 24
Active, not recruiting 25
Completed 116
Suspended 1

Showing 5 of 8 statuses.

Start your 14-day trial Email me all 8 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Ependymoma trials? (5)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 33
Children's Oncology Group 5
European Organisation for Research and Treatment of Cancer - EORTC 4
National Institutes of Health Clinical Center (CC) 4
Pediatric Brain Tumor Consortium 4

Which drugs are being tested for Ependymoma? (3)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Cytoxan 13
NIVOLUMAB 5
Irinotecan 5

Interventions as named in the registry (12)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
SOC: Temozolomide 25
Etoposid 13
Filgrastime (G-CSF) 10
Positron Emission Tomography (PET) 10
Radiation Therapy 10

Showing 5 of 12 interventions.

Start your 14-day trial Email me all 12 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Ependymoma trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Seizure 47 19
Headache 30 16
Vomiting 24 11
Nausea 21 12
Death NOS 19 10

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Ependymoma? (53)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Phase I study of gene-mediated cytotoxic immunotherapy with AdV-tk as adjuvant to surgery and radiation for pediatric malignant glioma and recurrent ependymoma. Neuro-oncology 2019 Yes
A systematic review and meta-analysis of outcomes in pediatric, recurrent ependymoma. Journal of neuro-oncology 2019 Yes
Imaging biomarkers of outcome after radiotherapy for pediatric ependymoma. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2018 Yes
Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas. Acta neuropathologica 2018 Yes
Pediatric Localized Intracranial Ependymomas: A Multicenter Analysis of the Société Française de lutte contre les Cancers de l'Enfant (SFCE) from 2000 to 2013. International journal of radiation oncology, biology, physics 2018 Yes

Showing 5 of 53 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Prevalence (6)

Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.

Prevalence
Orphanet disease Type Class Geography Jurisdiction Mapping relation
Ependymoma Point prevalence Unknown Europe Not stated Exact
Ependymoma Point prevalence Unknown Europe Not stated Exact
Ependymoma Point prevalence Unknown Europe Not stated Unspecified
Ependymoma Annual incidence 1-9 / 1 000 000 Europe Not stated Exact
Ependymoma Annual incidence 1-9 / 1 000 000 Europe Not stated Exact

Showing 5 of 6 prevalence observations.

Start your 14-day trial Email me all 6 prevalence observations as a PDF

Rare-disease identity (2)

Shown in this order: exact, broader, narrower, other.

Rare-disease identity
Orphanet disease ORPHA code Relation Source
Ependymoma 251636 Exact Orphadata Science knowledge files, Product 1
Ependymoma 251636 Exact Orphanet Rare Disease Ontology (ORDO)

Sub-conditions in MeSH (1)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Browse all condition evidence pages